Advantages Disadvantages
Requirement of only one sample preparation. Simplicity of analysis and assessment. Suitable pharmacokinetic parameter for vancomycin TDM in patients with non-severe MRSA and non-MRSA infections [9]. Possible errors in exact sampling times [14]. Enhanced risk of vancomycin-associated nephrotoxicity and AKI due to vancomycin over-dose therapy with a target concentration of 15-20 µg/ml [19]. Higher risk of failure in therapy [22]. Lack of clinical efficacy for the target trough concentration of 15-20 µg/ml [12, 22]. No significant correlation with the AUC-based monitoring approach [14, 24]. Not recommended in patients with severe MRSA infections [9].